(BIVI) BioVie Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BIVI) BioVie Inc. Complete Analysis Pack
BioVie Inc. Business Model Canvas: Strategy at a Glance
Unlock the full strategic blueprint behind BioVie Inc.'s business model. This concise Business Model Canvas breaks down how the company creates value, builds partnerships, and positions itself in a competitive biotech market. Ideal for investors, analysts, and strategists—get the full version to see the complete picture.
Partnerships
U.S. clinical trial sites
BioVie Inc. depends on U.S. clinical trial sites to run its Phase III Alzheimer’s study and Phase I Parkinson’s study across multiple centers. These networks handle screening, dosing, safety checks, and endpoint collection, and they are critical for recruiting and keeping participants in long trials.
CROs and data management vendors
BioVie Inc. depends on CROs and data management vendors to run trials, monitor sites, clean databases, and support biostatistics, which keeps its internal team lean. This matters in a pipeline-driven biotech model, because outsourced clinical operations can handle most case reporting and data handling work across studies while BioVie focuses cash and staff on development.
CMOs and formulation suppliers
BioVie Inc. relies on CMOs and formulation suppliers to make, package, and ship clinical-grade material for BIV201 and NE3107, so supply stays consistent across trials. This matters because drug development depends on tight quality control and scale-up support, and BioVie’s market cap has stayed under $100 million in recent filings, which makes outsourcing more practical than building in-house capacity.
Physician investigators and research institutions
BioVie Inc. relies on physician investigators and research institutions to design and run human studies, with key opinion leaders adding hands-on expertise in 3 core areas: neurology, liver disease, and oncology. Their role improves site activation, patient recruitment, and study credibility, which is critical for small biotech programs that need fast, trusted execution.
- Expert input across 3 therapeutic areas
- Helps recruit and retain trial patients
- Raises scientific credibility with regulators
Equity investors and financing partners
BioVie relies on equity investors and financing partners because, as a clinical-stage biotech, it has little or no product revenue and must fund R&D, trials, and G&A from external capital. In its latest filings, ongoing losses and negative operating cash flow mean public and private funding still support runway and keep development moving.
- Funds trial spend before sales
- Extends operating runway
- Supports development continuity
BioVie’s Trial Partners Power Its Alzheimer’s and Parkinson’s Bets
BioVie Inc. depends on CROs, CMOs, and U.S. trial sites to run its Phase III Alzheimer’s and Phase I Parkinson’s programs, while physician investigators and research centers help recruit patients and keep studies credible. As a clinical-stage biotech with no product sales, it also relies on equity and financing partners to fund R&D and trial spend.
| Partner | Role | Why it matters |
|---|---|---|
| CROs and CMOs | Run trials and make drug supply | Keep BioVie lean and funded |
| Sites and investigators | Enroll and monitor patients | Support data quality and speed |
What is included in the product
Detailed Word Document
A concise, real-world BMC overview of BioVie Inc.'s biotech model, covering R&D, patient value, partners, and commercialization strategy.
Customizable Excel Spreadsheet
Quickly maps BioVie Inc.’s pain-point relief model in a clear, one-page snapshot.
Reference Sources
Provides a credible source trail for BioVie Inc. that helps validate assumptions, speed due diligence, and support confident decision-making.
Activities
NE3107 Phase III Alzheimer’s development
BioVie’s key activity is advancing NE3107 in a Phase III study for mild to moderate Alzheimer’s disease, its most advanced program. The work centers on enrolling patients, dosing, safety monitoring, and endpoint analysis, with the readout designed to test cognitive and clinical benefit in a late-stage setting.
NE3107 Phase I Parkinson’s development
BioVie Inc. is running NE3107 in a Phase I Parkinson’s study focused on safety, tolerability, and dose finding. The program extends NE3107 into another neurodegenerative market, adding to a Parkinson’s disease field that affects about 10 million people worldwide.
BIV201 cirrhosis ascites development
BioVie’s key activity is advancing BIV201, which completed a Phase IIa study in ascites from chronic liver cirrhosis, a serious complication that affects patients with advanced liver disease. The next step is follow-on development and evidence generation to support later-stage testing and a stronger clinical package for this liver indication.
Preclinical oncology exploration
BioVie Inc. is extending NE3107 beyond neurology with preclinical oncology work in multiple myeloma and prostate cancer. The goal is to test new uses in two high-need cancer areas and widen the pipeline with data that can support later-stage studies.
- NE3107: preclinical oncology use
- Targets multiple myeloma
- Tests prostate cancer
- Broadens pipeline beyond neurology
Regulatory, CMC, and fundraising work
BioVie Inc. must keep close FDA and CMC (chemistry, manufacturing, and controls) work in step with its trials, including filings, safety reports, and protocol compliance. As a clinical-stage Company Name with no commercial product revenue, it also has to raise capital often, so investor updates and financing execution are core operating tasks.
- FDA filings and safety reporting
- CMC and trial compliance
- Equity or debt fundraising
BioVie Advances NE3107 and BIV201 Amid Capital-Raising Push
BioVie Inc.'s key activities stay centered on NE3107 clinical development in Alzheimer's and Parkinson's disease, plus BIV201 follow-on work in ascites from cirrhosis and preclinical oncology studies in multiple myeloma and prostate cancer. The Company also keeps FDA, CMC, and capital-raising work moving because it has no commercial product revenue.
| Key activity | Stage | Focus |
|---|---|---|
| NE3107 | Phase III | Alzheimer's disease |
| BIV201 | Post-Phase IIa | Cirrhosis ascites |
| NE3107 | Preclinical | Myeloma, prostate cancer |
Full Version Awaits
Business Model Canvas
This BioVie Inc. Business Model Canvas preview is the exact document you’ll receive after purchase. It’s not a sample or placeholder—what you see here is a real snapshot of the final file. Once your order is complete, you’ll get the same professionally formatted document, ready to use right away.
Resources
NE3107 lead asset
NE3107 is BioVie Inc.'s main clinical-stage asset, with Phase III Alzheimer's disease and Phase I Parkinson's disease programs. As the company’s lead molecule, it is the core driver of future value and any shift in trial outcomes can materially affect BioVie Inc.'s outlook.
BIV201 lead asset
BIV201 is BioVie’s lead liver-disease asset and its key clinical resource. It has already completed a Phase IIa trial in ascites associated with chronic cirrhosis, giving BioVie human safety and efficacy data to support next-step partnering and funding decisions.
Clinical data package
BioVie Inc.’s clinical data package spans 3 study stages—Phase I, Phase IIa, and Phase III—and is a core asset for dose, indication, and go/no-go decisions. It also supports regulatory talks, investor updates, and partnering, where trial readouts often move valuation more than sales do.
Intellectual property and know-how
BioVie Inc.’s patents, formulations, and development know-how help protect its drug pipeline and make it harder for rivals to copy its work. In biotech, IP is the core asset, because it supports exclusivity, raises partnering value, and can shape future licensing terms.
- Protects pipeline exclusivity
- Supports partnering leverage
- Improves licensing economics
Scientific team and Carson City headquarters
BioVie’s core resource is its Carson City, Nevada base, where internal scientific and regulatory leadership steers the pipeline and coordinates external vendors. For a small biotech, that lean setup is critical because it keeps R&D and compliance decisions close to the team while limiting fixed overhead.
- Carson City headquarters anchors operations.
- Internal team handles science and regulation.
- External vendors extend capacity without bloating staff.
BioVie’s Value Hinges on NE3107, BIV201, and Clinical Data
BioVie Inc.’s key resources are its clinical assets, NE3107 and BIV201, plus the IP and trial data that back them. As of FY2025, the company reported $0 revenue and relied on R&D-linked assets, not sales, to drive value.
| Resource | FY2025 / FY2026 data |
|---|---|
| NE3107 | Phase III AD; Phase I PD |
| BIV201 | Phase IIa ascites data |
Value Propositions
Phase III Alzheimer’s candidate
BioVie’s Phase III candidate for mild to moderate Alzheimer’s gives BioVie Inc. a higher-maturity asset than early-stage programs, which can matter to partners and investors. With about 6.9 million Americans age 65+ living with Alzheimer’s and no cure today, a late-stage program offers clearer clinical and commercial upside than preclinical research.
Completed Phase IIa liver program
BIV201 has already cleared a Phase IIa study in ascites from chronic liver cirrhosis, giving BioVie Inc. human clinical proof in a high-need liver market. Ascites is a major cirrhosis complication and often drives hospital care, so a completed trial strengthens credibility for future development and partnering.
Multiple neurodegenerative indications
NE3107 is being tested in both Alzheimer’s disease and Parkinson’s disease, so one asset can pursue two large CNS markets. Alzheimer’s affects over 55 million people worldwide and Parkinson’s about 10 million, giving BioVie Inc. more clinical paths and stronger strategic optionality if one indication advances faster than the other.
Oncology expansion potential
BioVie Inc.'s NE3107 cancer work could widen the value story beyond neurology: multiple myeloma caused about 35,000 new U.S. cases in 2025, while prostate cancer is still the most common male cancer, with about 313,780 new U.S. cases expected in 2026. Even as preclinical assets, these programs can diversify the pipeline and open much larger oncology markets.
- Multiple myeloma: ~35,000 U.S. cases in 2025
- Prostate cancer: ~313,780 U.S. cases in 2026
- Broader pipeline lowers single-therapy risk
U.S.-based clinical-stage development platform
BioVie Inc. offers a U.S.-based clinical-stage platform built around drug discovery, development, and commercialization. Its value lies in combining clinical execution with a broader pipeline, so stakeholders get one team that can move programs from early testing toward market-ready assets.
- U.S.-based clinical-stage focus
- Drug discovery to commercialization
- Clinical execution plus pipeline breadth
That mix supports faster development decisions and a clearer path to future product value.
BioVie’s Late-Stage Pipeline Offers Real Human Data and Partnering Potential
BioVie Inc.’s value proposition is a late-stage CNS and liver pipeline with real human data: NE3107 is in Phase III for Alzheimer’s, while BIV201 has Phase IIa proof in cirrhosis ascites. That mix gives BioVie Inc. a clearer shot at partnering and value creation than preclinical-only peers.
| Program | Stage | Why it matters |
|---|---|---|
| NE3107 | Phase III | Alzheimer’s upside |
| BIV201 | Phase IIa | Human liver data |
Customer Relationships
Investigator-led collaboration
BioVie’s customer relationships are investigator-led and centered on clinical investigators and site teams, not quick sales. These ties are technical and long-cycle, because they support protocol execution, patient follow-up, and data quality across its ongoing clinical programs, including the 225 mg and 450 mg zilucoplan dose levels used in its recent study work.
Patient enrollment support
Patient enrollment support at BioVie Inc. runs through study sites, where clinicians and coordinators recruit, screen, and follow participants. This is vital in neurological and cirrhosis trials, where site-based oversight helps keep consent, visits, and safety tracking tight across small, hard-to-reach patient pools.
Safety monitoring and reporting
BioVie Inc. uses continuous adverse-event tracking in its trials, with sites and monitors feeding safety data to regulators in real time; serious events must be reported fast under FDA rules, often within 7 or 15 days depending on severity. That discipline builds trust, supports compliance, and helps keep studies audit-ready.
Investor communications
BioVie Inc. keeps investor relationships through SEC reporting and regular corporate updates, which is key for a development-stage public biotech. Investors track trial progress and financing closely because those disclosures can shape access to capital and the terms of future raises.
- SEC filings keep BioVie Inc. visible
- Trial updates can move funding access
- Financing disclosure supports trust
Partnering dialogue
BioVie’s partnering dialogue is science-led and milestone-based, so licensing talks can start as data readouts improve. These deals can bring non-dilutive funding, which matters for a small biotech with limited cash runway and high trial costs.
- Science first, not sales pitch
- Milestones shape deal terms
- Can fund later work without dilution
BioVie’s Clinical Ties and Investor Signals Shape Its Path
BioVie Inc. builds customer relationships through investigators, site teams, and regulators, so the ties are clinical, not transactional. Patient support and safety tracking run at the site level, where fast adverse-event reporting follows FDA timing rules of 7 or 15 days for serious events.
Investor ties matter too, because SEC updates on trial progress and financing can affect capital access for a development-stage biotech.
| Relationship | Key data |
|---|---|
| Trial sites | 225 mg and 450 mg zilucoplan |
| Safety reporting | 7 or 15 days |
| Investor updates | SEC filings |
Channels
U.S. clinical trial sites
U.S. clinical trial sites are BioVie Inc.’s main channel for delivering investigational therapies, linking the company with patients and principal investigators. They also produce the source data BioVie needs for safety and efficacy readouts, which is the core input for FDA development decisions.
Physician investigators and referrals
Specialist physicians are the main referral gate for BioVie Inc.’s Alzheimer’s disease, Parkinson’s disease, and cirrhosis studies, because they can spot eligible patients faster than broad outreach. In the U.S., Alzheimer’s affects about 7.2 million adults age 65+ and Parkinson’s about 1 million people, so physician referrals help speed enrollment and improve study fit.
SEC filings and press releases
BioVie Inc. uses SEC filings and press releases to keep investors updated on trial status, financing, and corporate events. As a publicly traded company, it must file reports like Form 10-K and 10-Q with the SEC, so these channels are the main source for timely disclosures.
Medical congresses and publications
Scientific congresses and peer-reviewed publications help BioVie Inc. share trial updates with physicians, investigators, and potential partners, which can speed awareness of its programs. They also serve as external validation, since medical conferences and journals are key channels for review by the clinical community.
- Shares clinical data fast
- Builds medical credibility
- Supports partner diligence
For a development-stage biotech, this channel matters because trust is built on published evidence, not marketing. Strong abstracts, posters, and journal papers can improve researcher interest and help de-risk collaboration talks.
Direct business development outreach
BioVie Inc. uses direct business development outreach to contact potential licensing and co-development partners, which helps expand its pipeline and can bring in non-dilutive funding. For a small biotech, this channel matters because strategic deals can support R&D when cash is tight and external capital is expensive.
- Targets licensing partners
- Supports pipeline expansion
- Helps secure financing support
BioVie’s Low-Cost Channels Power Trial Enrollment and Investor Confidence
BioVie Inc.’s channels are still mainly clinical trial sites, specialist physician referrals, investor disclosures, congresses, and direct partner outreach. In FY2025, cash used in operations was about $16.3 million, so these low-cost channels matter for enrollment, credibility, and funding.
| Channel | Role | FY2025 |
|---|---|---|
| Trial sites | Enroll patients | Core |
| SEC filings | Inform investors | Mandatory |
Customer Segments
Mild to moderate Alzheimer’s disease patients
Mild to moderate Alzheimer’s disease patients are BioVie Inc.'s core NE3107 Phase III target. In the U.S., about 6.9 million people age 65+ live with Alzheimer’s disease, and this group faces ongoing cognitive decline and very limited treatment options, making it a large unmet-need market.
Parkinson’s disease patients
Parkinson’s disease patients are a large neurodegenerative segment, with about 10 million people affected worldwide, and BioVie Inc.'s NE3107 is also being tested in this area. That gives the Company Name access to a second brain-disease market beyond Alzheimer’s, broadening its therapeutic reach and linking it to a high-need, long-duration treatment group.
Ascites from chronic liver cirrhosis patients
BioVie’s BIV201 targets patients with cirrhosis-related ascites, the largest liver-disease segment in its model. Ascites affects about 50% of people with cirrhosis within 10 years, and once it appears, 1-year mortality can reach roughly 20% to 50%, making this a severe, high-need group for repeated treatment.
Multiple myeloma and prostate cancer research populations
BioVie Inc.’s NE3107 oncology work targets two research-only customer segments: multiple myeloma and prostate cancer populations. Global burden stays large, with about 180,000 new multiple myeloma cases and 1.5 million prostate cancer cases each year, so even preclinical success could open a major future market.
- Preclinical only, not yet clinical
- High-incidence, future expansion markets
- Large unmet need in oncology
Pharmaceutical licensing partners
Pharmaceutical licensing partners are a key customer segment for BioVie Inc. because they can fund development, co-develop programs, or license assets before approval and after launch. For clinical-stage biotech, these deals often hinge on milestone cash, royalties, and shared trial risk, so partner fit can decide whether a program reaches market.
- Fund trials and reduce cash burn
- Share development and regulatory risk
- Use pre- and post-approval
BioVie Targets Alzheimer’s, Parkinson’s, Cirrhosis, and Pharma Partners
BioVie Inc. serves four main customer groups: Alzheimer’s patients, Parkinson’s patients, cirrhosis-related ascites patients, and future oncology patients. It also targets pharma licensing partners that can fund trials, share risk, and pay milestone and royalty economics.
| Segment | Need | Scale |
|---|---|---|
| Alzheimer’s | NE3107 Phase III | 6.9M U.S. 65+ |
Cost Structure
Phase III trial costs
Phase III work is usually a biotech’s biggest cash drain, and for BioVie Inc.’s NE3107 program it is a major line item. Costs come from enrollment, site fees, patient monitoring, data management, and final analysis; late-stage trials can run into tens of millions of dollars, so faster recruitment and clean data are key to protecting cash.
Phase I and preclinical spend
BioVie Inc.’s Phase I and preclinical spend covers animal studies, biomarker work, and early safety tests for Parkinson’s and oncology. These steps are smaller than Phase III, but they still matter: Phase I often enrolls about 20 to 80 people, while preclinical work can run 12 to 24 months and drive meaningful lab and CRO costs.
CRO and CMO fees
BioVie Inc. relies on CRO and CMO vendors to run trials and supply drug product, so these recurring contracts take a large share of R&D spend. In the latest 2025 reporting cycle, BioVie had no product revenue and still carried multi-million-dollar development costs, which makes outsourced study and manufacturing fees a core cost driver.
Payroll and headquarters overhead
BioVie Inc. keeps a fixed cost base in payroll and headquarters overhead: scientific, regulatory, and executive staff support the pipeline, while Carson City corporate operations add rent, systems, and admin spend. For a public biotech, these costs stay on even before product revenue, so they shape burn rate and runway.
FY2025 filing data should be used to pin down the exact salary and G&A load, but the structure is clear: people plus HQ costs fund development, compliance, and listing duties. That makes overhead a core driver of cash use, not just a back-office item.
- Pipeline staff drive payroll
- Carson City adds rent and systems
- Public-company overhead is fixed
Regulatory, legal, and IP spend
BioVie Inc. must keep paying for FDA filings, legal contracts, and patent work to protect its pipeline; in biotech, IP defense can run into millions, and a U.S. patent can cost $20,000+ to file and keep alive over time. These costs are not optional—they help defend future exclusivity and value.
- Compliance keeps trials and filings on track
- Patents defend pipeline value
- Legal spend rises with licensing and disputes
BioVie’s Burn Still Runs on R&D, with No Revenue Cushion in FY2025
BioVie Inc.’s cost base is still mostly R&D: Phase III enrollment, sites, monitoring, CRO/CMO fees, and data analysis drive the burn, while payroll and Carson City overhead keep running before revenue. In FY2025, BioVie Inc. reported no product revenue, so development and public-company costs remained the main cash use.
| Cost item | Why it matters |
|---|---|
| Phase III trials | Largest spend |
| CRO/CMO contracts | Outsourced ops |
| Payroll + HQ | Fixed burn |
Revenue Streams
Equity offerings
BioVie, a clinical-stage biotech, had no commercial product revenue in FY2025, so equity offerings are a key near-term funding source. It can raise cash through public or private stock sales, including at-the-market issuance, to fund trials and overhead; for pre-revenue biotechs, this is often the main capital path.
Upfront collaboration fees
BioVie Inc. has had 0 commercial sales, so upfront collaboration fees from licensing or co-development deals can bring in non-dilutive cash before product revenue starts. For small biotech assets, these payments often fund R&D and can bridge the gap to Phase 2 or Phase 3 data.
Development milestone payments
Development milestone payments could come from future licensing or partner deals tied to BIV201 or NE3107 hitting trial, FDA, or other regulatory steps. BioVie Inc. has no approved revenue products, so even modest upfront and milestone cash would help fund R&D and reduce dilution pressure from new share issuance.
Research grants and non-dilutive funding
BioVie Inc. is still pre-revenue, so research grants and other non-dilutive funding can help pay for early-stage trials and exploratory work without issuing new shares. This matters when R&D is cash-heavy: every grant dollar can reduce dilution and preserve capital for the most promising programs.
- Funds early, high-risk research
- Offsets R&D spend without dilution
- Supports selective programs only
Future royalties and product sales
BioVie Inc. has no commercial product revenue yet; in FY2025 it remained pre-commercial with $0 in product sales. If its drug candidates win FDA approval, future income could come from direct sales or licensing royalties, but only after successful clinical and regulatory milestones.
- FY2025 product sales: $0
- Revenue depends on approval
- Can earn sales or royalties
BioVie Stays Pre-Revenue, Eyes Future Cash from Funding and Licensing
BioVie Inc. stayed pre-revenue in FY2025, with $0 in product sales. Near-term cash mainly comes from equity raises, while future revenue would need licensing, milestones, or eventual drug sales after approval.
| Revenue stream | FY2025 |
|---|---|
| Product sales | $0 |
| Equity funding | Primary cash source |
| Licensing and milestones | Potential future cash |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.